As an autologous product, the donor of the tissue and the recipient of the cells are the same person. This fact highly reduces problems commonly associated with allogenic products. The risks of rejection are greatly reduced. The risks of allergic reaction are also highly reduced.
IntelliCell™ does not culture, grow, or expand the cells in any way. This is important to clinicians and patients alike. There is no growth serum used in the process, such as growing cells in bovine serum and there are no enzymatic agents in use, such as collagenese. IntelliCell™ thinks that its process results in a minimal manipulation of the originating vascular tissue and the final cellular product. Ultrasound, which has been in clinical use for decades, is the method by which IntelliCell™ is able to obtain the Vascular Fraction Cells.
The IntelliCell™ process also results in much higher cellular yields when compared to other methods in clinical research use today.
For the clinician using the IntelliCell™ product, it is a same day procedure. This is more convenient for the patient and the clinician.
Unlike most companies that use other types of equipment, IntelliCell™ uses a flow cytometer to check each sample for cell viability and the cell count for each patient. This is an important quality step that permits IntelliCell™ to generate the safety data that is required to adhere to good laboratory practices.
The entire process takes about 1 hour to complete. The cells are then returned to the physician and the patient treatment can begin. Some of the cells are placed into an IV drip bag for administration. The IV treatment takes about 20 minutes. Depending on the areas being treated and the type of injury, cells can be also be placed locally.
"'Feeding a hungry planet Over the last 30 years, Brazil has transformed itself into a breadbasket, and it's done so in large measure by dramatically increasing farm inputs. The government is seeking to close that loop, putting pressure on the industry to triple spending on domestic fertilizer capacity over the course of the next five years.
Why might the country want to become less reliant on imports? Beyond the usual national security arguments, there's the matter of competitiveness. Transportation of nutrients to inland farms from ports can be very expensive and time consuming. As a result, Brazil's farmers are losing out to countries like the U.S.
To address this issue, Brazil's government wheedled miner Vale SA (ADR) (NYSE:VALE), in which it has a golden share, to invest in potash and phosphates. Vale's investment plan now calls for $8.8 billion in spending on fertilizers over the next five years"'
.Some dd and just great to have the chance to grab some shares at this ultra low price
I am putting some money in SKBI. What you think about CSKI, looks very cheap too. Do you have something else to recommend in the china health-care? also any good company in the consumer sector?
I started to put some money in the market last week. No many choices really. I bought PUDA and LLEN today but looking to put some more money in China stocks. GFRE looks very cheap and have a lot of cash.
Can you recommend me something else in a different sector?